

Cite this: *Chem. Sci.*, 2017, **8**, 8427Received 28th September 2017
Accepted 23rd October 2017DOI: 10.1039/c7sc04204c
rsc.li/chemical-science

Introduction

Phosphates are essential for cellular energy, metabolism, structure, and function, thus, enzymes that are able to transfer phosphate are crucial for cell survival.^{1,2} The haloacid dehalogenase (HAD) superfamily contain enzymes that catalyze phosphotransferase reactions with the use of Mg^{2+} as a cofactor and a conserved aspartic acid residue acting as a nucleophile.³ A member of this superfamily, β -phosphoglucomutase (β PGM), is able to concisely perform two different phosphotransfer reactions in the same active site while accelerating rates of conversion by a factor of 10^{21} . β PGM catalyzes the conversion of β -glucose-1-phosphate (β G1P) into glucose-6-phosphate (G6P) via a ping-pong mechanism (Fig. 1A).^{4,5}

Studies on the enzyme structure of β PGM reveal that the protein is monomeric, containing a helical cap domain and an α/β core domain with its active site at the interface.⁴ Upon binding of β G1P, the structure of β PGM changes from its “cap-open” conformation to its “cap-closed” conformation by the rigid rotation of its cap domain.⁶ The phosphorylated aspartic acid residue (Asp8) transfers its phosphate to the 6-OH of β G1P

producing a β -glucose-1,6-bisphosphate (β G16BP) intermediate causing the enzyme to convert to its “cap-open” conformation. β G16BP dissociates from the enzyme, repositioning itself to allow for dephosphorylation of the phosphate at C-1, before it rebinds to the enzyme prompting it to convert back into its “cap-closed” conformation. Recent attempts to further understand the two-step mechanism of β PGM have been made by using metal fluorides to form transition state analogue (TSA) complexes.⁷⁻⁹ Studies have shown that MgF_3^- and AlF_4^- are able to closely mimic the charge and geometry of the transferred phosphate such that they can form long-lived complexes with various substrate analogues.^{9,10} G6P complexes were successfully isolated and analyzed (Fig. 1B) as a representation of transition state 2 (TS2) of the enzymatic reaction, however, complexes with β G1P were inaccessible as a result of its turnover.⁸ To solve this problem, methylenephosphonate and α -fluoromethylenephosphonate analogues of β G1P were synthesized to enable formation of the TSA complexes (Fig. 1B), mimicking step 1 (TS1) of the enzymatic reaction.⁷ Crystallographic evidence of TSA complexes revealed that TSA complexes for step 1 involve direct contact of amino acid residues with the substrate, while TSA step 2 complexes involve two conserved water molecules bridging the substrate and amino acid residues.⁷ Although the ability of β PGM to readily form stable metal fluoride complexes provides a ^{19}F spectroscopic probe to detect stable TSA complex formation, it lacks a direct enzymatic signal and questions whether metal fluoride TSA complexes are representative of the enzymatic reaction coordinate. Incorporating a spectroscopic probe into the enzyme would test this hypothesis. Further, it would offer the opportunity to screen and analyze inhibitors without the use of metal fluorides. The

^aDepartment of Chemistry, Dalhousie University, Halifax, NS, Canada B3H 4R2.
E-mail: david.jakeman@dal.ca

^bEuropean Molecular Biology Laboratory, Grenoble Outstation, 71 avenue des Martyrs, CS 90181 F-38042 Grenoble, France

^cCollege of Pharmacy, Dalhousie University, Halifax, NS, Canada B3H 4R2

^dProteomics and Mass Spectrometry Core Facility, Life Sciences Research Institute, Dalhousie University, Halifax, NS, Canada B3H 4R2

† Electronic supplementary information (ESI) available: Supporting Figures, HQSC NMR spectra, LC-MS/MS data and X-ray diffraction refinement data are described. See DOI: [10.1039/c7sc04204c](https://doi.org/10.1039/c7sc04204c)






Fig. 1 (A) Enzymatic mechanism of β PGM converting β G1P to G6P via a β G16BP intermediate. Conversion occurs through a bi bi ping-pong mechanism allowing the intermediate to reorient itself in the enzyme active site. (B) Inhibition of step 1 and 2 of the enzymatic reaction by the formation of previously reported TSA complexes.^{7,8}

use of fluorine as a spectroscopic probe has monitored conformational changes and protein-ligand binding.¹¹⁻²³ Herein, we present the use of fluorine as a spectroscopic probe on β PGM to provide insight into ternary TSA complexes of phospho-transfer enzymes, and demonstrate that the concentration of the fluorinated enzyme directly correlates to the concentration of the metal fluoride complexes in aqueous solution.

Results and discussion

Expression of ^{19}F -labeled β PGM

Incorporation of fluorine into the β PGM enzyme structure was accomplished by use of 5-fluorotryptophan (5FW). The β PGM structure contains two tryptophan residues, W24 and W216. Analysis of a previously recorded crystal structure of β PGM with a TSA complex (PDB ID code 4C4R)⁷ reveals that W24 is on the enzyme cap domain and W216 is on the enzyme core domain. W24 is within ~ 3 Å of the active site, allowing the indole nitrogen to form a hydrogen bond with the substrate during catalysis, while W216 is on the outer surface of the core domain, ~ 22 Å from the active site, and is not in direct contact with the substrate (Fig. S1†). Since the two tryptophan residues are located on different domains, we anticipated that these differences in environment would result in distinct ^{19}F resonances by ^{19}F NMR spectroscopy.

^{19}F -labelling was incorporated into the wild-type β PGM as well as a W24F and W216F β PGM mutants. To substitute the natural tryptophan residues for ^{19}F -tryptophan, two different methods were explored. The first protocol was developed by Crowley and coworkers²⁴ who found that upon addition of 5-fluoroindole to cell media, *E. coli* BL21 cells were able to incorporate the fluorinated indole into tryptophan biosynthesis (method A). The second protocol involved the use of glyphosate to induce aromatic amino acid auxotrophy, followed by the addition of 5-fluorotryptophan, unlabeled phenylalanine, and

unlabeled tyrosine (method B).²⁴ Both methods did not show any major deleterious effect on protein overexpression or purification, however, the yields observed for the production of 5-fluorotryptophan β PGM (5FW β PGM) were $\sim 47\%$ for method 1 and $\sim 85\%$ for method B compared to the wild-type β PGM. Incorporation of ^{19}F -labeled amino acids are known to inhibit bacterial growth to different degrees.²¹

Efficacy of ^{19}F -labeling methods

To analyze the efficacy of both labelling methods, ^1H - ^{15}N HSQC and LC-MS/MS were performed. Upon ^{15}N -labeling of 5FW β PGM produced by method A, we expected the ^1H - ^{15}N HSQC of the labeled protein to show cross peaks for all nitrogen resonances except the two 5-fluoroindole tryptophan side chains. Therefore, comparing the integrations of the cross peaks from the tryptophan backbone and tryptophan side chain resonances would provide a quantitative analysis of 5-fluoroindole incorporation (method A). ^{15}N -labeling of 5FW β PGM produced by method B would result in an unlabeled side chain and backbone nitrogen for 5FW residues, which would be absent from the ^1H - ^{15}N HSQC. Comparing the integration of the tryptophan backbone cross peak to a backbone residue close in proximity in the enzyme structure would, therefore provide a quantitative analysis of 5-fluorotryptophan incorporation. An HSQC spectra overlay of the wild-type ^{15}N -labeled β PGM and the ^{15}N -labeled β PGM from method A and B (Fig. S8†) revealed that the incorporation of both ^{19}F -labeled tryptophan residues did not cause any structural perturbations in the enzyme tertiary structure, while suggesting high efficacy labelling with both methods. The HSQC spectra for both methods A and B showed an absence of the distinct Trp side chain cross peaks as seen in the ^{15}N -labeled β PGM spectra which we interpreted as a high percent incorporation of ^{19}F -labeled tryptophan (Fig. S9-11†). To more accurately quantify the effects of labeling, LC-MS/MS analysis of the peptides showed corresponding masses for fragments containing tryptophan (W24 and W216) and






Fig. 2 ^{19}F NMR spectra of ^{19}F -labelled wild-type and W24F mutant βPGM . Diamonds (◆) are 5FW216 resonances and circles (●) are free MgF_3^- resonances (~155 ppm). Resonances at ~119 are from free F^- . Assignment of MgF_3^- and AlF_4^- resonances were previously determined by chemical shift.^{21,33} Assignment of MgF_3^- and AlF_4^- resonances were previously determined by chemical shift.^{21,33} (A) 5FW βPGM ; (B) W24F, 5FW216 5FW βPGM ; (C) W24F, 5FW216 5FW βPGM - MgF_3^- -G6P TSA complex.

corresponding masses for fragments containing fluorotryptophan (5FW24 and 5FW216). To generate peptides, endo-proteinase Lys-C was used to digest βPGM . A ratio between the total ion count of fragments containing 5FW24 : W24 and 5FW216 : W216 provided a quantitative result of each method. Method A showed ~70% incorporation of 5-fluoroindole and method B showed ~85% incorporation of 5-fluorotryptophan. We, therefore, chose to use method B to produce 5FW βPGM since both the levels of incorporation and quantity of protein production were highest.

^{19}F NMR analysis of 5FW βPGM and assignment of resonances

The three protein constructs, W24F, W216F and wild-type βPGM were induced using method B and the recombinant purified 5FW proteins isolated. For the wild-type 5FW24 5FW216 βPGM there were three major resonances present in the 1D ^{19}F NMR spectrum at ~120, ~123.5, and ~125 ppm (Fig. 2A). The resonance seen at ~123.5 ppm was noticeably broad showing the presence of a second species. The ^{19}F NMR spectrum for the 5FW216 W24F mutant showed two broad resonances at ~123.5 ppm and ~125 ppm (Fig. 2B). The occurrence of two resonances corresponding to one 5FW residue could be attributable to a 5-fluoroindole ring flip, or

a core domain conformation not observed crystallographically (*vide infra*).^{25,26} For the 5FW24 W216F ^{19}F NMR spectrum, a single resonance observed at ~123.7 ppm that was readily assigned to the 5FW abutting the active site (Fig. 3A) and, therefore, be most likely to report upon the formation of TSA complexes. All three of the 5FW protein constructs were subjected to conditions to form TSA complexes for both TS1 and TS2 and with MgF_3^- or AlF_4^- (Fig. S12 and S13†). All of the 5FW protein constructs formed TSA complexes as observed by the characteristic three signals in MgF_3^- complexes, or the characteristic four signals in the AlF_4^- complexes in the ^{19}F spectra. The chemical shifts for the metal fluoride complexes were consistent with previous literature reports for TSA1 and TSA2. Fig. 2C shows the formation of the W24F 5FW216 βPGM - MgF_3^- -G6P TSA2 complex. This is the fluorinated βPGM where the 5FW is remote from the active site. That the two resonances present from the 5FW216 did not change intensity or chemical shift appreciably is suggestive that residue W216, being remote from the active site (~22 Å), does not function effectively as a probe of TSA formation. It also indicates that the core domain where W216 is located, does not undergo a conformational change, observable by ^{19}F NMR of the 5FW216, upon formation of a TSA complex. The formation of the W216F 5FW24- MgF_3^- -G6P TSA2 complex is shown in Fig. 3B. In this instance, the




Fig. 3 ^{19}F NMR spectra of the 5FW βPGM W216F mutant and its TSA1 and TSA2 complexes. Asterisks (*) are TSA 5FW24 resonances, squares (■) are apo 5FW24 resonances, circles (●) are free MgF_3^- , inverse triangles (▼) are complexed $\text{G1C}_5\text{FP}$, triangles (▲) are free $\text{G1C}_5\text{FP}$. (A) W216F 5FW βPGM ; (B) W216F 5FW βPGM - MgF_3^- -G6P TSA complex; (C) W216F 5FW βPGM - AlF_4^- - $\text{G1C}_5\text{FP}$ TSA complex.

Table 1 Kinetic parameters for wild-type and 5FW β PGM with native substrate and competitive inhibitors

	Wild-type β PGM	5FW β PGM
K_m	$9.0 \pm 0.7 \mu\text{M}$	$10.1 \pm 2.1 \mu\text{M}$
k_{cat}	$7.7 \pm 0.1 \text{ s}^{-1}$	$3.8 \pm 0.1 \text{ s}^{-1}$
IC_{50} (β G1CP)	$18 \pm 3 \mu\text{M}$	$13 \pm 5 \mu\text{M}$
IC_{50} (β G1CF _S P)	$15 \pm 2 \mu\text{M}$	$11 \pm 2 \mu\text{M}$
$K_{i(\text{comp})}$ (β G1CP)		$4.67 \pm 0.04 \mu\text{M}$
$K_{i(\text{comp})}$ (β G1CF _S P)		$4.03 \pm 0.03 \mu\text{M}$

singular peak at -123.7 ppm corresponding to the 5FW24 resonance adjacent to the active site had disappeared, and a new peak at -121.7 ppm had appeared, a change of 2 ppm. The intensity of the new peak at -121.7 was comparable to the intensity of the three peaks corresponding to the MgF_3^- resonances between -145 and -160 ppm. The appearance of the new peak at -121.7 ppm was indicative that all of the protein in aqueous solution was involved in the formation of the TSA2 complex with G6P. Next we looked at utilizing the ^{19}F probe to monitor the formation of the TSA1 complex. It is not possible to form TSA1 complexes using the substrate β G1P since it is readily turned over by the enzyme to product. Our initial attempts to form MgF_3^- complexes using the non-isomerizable and non-hydrolysable analogues of β G1P namely, β G1CP and β G1CF_SP,⁷ were confounded by the significantly less intense peaks arising from the MgF_3^- (Fig. S12 and S13 \dagger) in comparison to the intensity of the corresponding peaks in the W216F 5FW24- MgF_3^- -G6P and other complexes. These results are consistent with previously reported data stating the weaker binding affinity of β G1CP *versus* G6P.⁷ Upon addition of AlCl_3 to the solutions, however, distinct peaks of comparable intensity and consistent chemical shift to TSA1 complexes formed previously⁷ were observed, that were indicative of TSA1 formation (Fig. 3C and S12 and S13 \dagger). The W216F 5FW24- AlF_4^- - β G1CF_SP TSA1 complex is particularly insightful since the substrate analogue also possesses a fluorine atom. Thus, in this spectrum, there are fluorine resonances from the singularly

fluorinated protein 5FW24, from the AlF_4^- , that is an isoelectronic representative of the transferring phosphate, and from the fluorinated non-isomerizable and non-hydrolysable analogue. The peak at -215 ppm arises from the bound ligand, the four peaks at -160 , -141 , -138 and -131 arise from the AlF_4^- , and the signal at -122 from the 5FW24 in the TSA1 complex. All of these peaks had comparable integration, accepting that there are differing rates of relaxation for each type of fluorine. This unequivocally demonstrates that the AlF_4^- species is in a molar equivalence with the 5FW24 β PGM in aqueous solution. This corroborates the structure observed by X-ray crystallographic data,^{7,8} and dispels any notion that metal fluoride complexes are not representative of phosphoryl transfer and are merely bespoke artifacts.

Kinetic analysis of 5FW β PGM

Kinetic studies were performed for both wild-type and ^{19}F -labeled enzyme (Table 1) to confirm kinetic competence of the fluorinated enzyme. α -Fructose-1,6-bisphosphate was used as an activator²⁷ and the Michaelis–Menten equation was fitted to the steady-state velocity data to generate K_m and k_{cat} values. The K_m of β G1P was $10.1 \mu\text{M}$, which was comparable to previously recorded results ($14.7 \text{ }^{\mu}\text{M}$).²⁸ This suggests that the incorporation of two fluorine atoms into the enzyme structure, one adjacent to the active site and one distal to the active site, did not have an effect on the binding affinity of the native substrate. The k_{cat} value of the wild-type and ^{19}F -labeled enzyme was slightly lower than reported (17 s^{-1})²⁴ which could be a result of the incorporation of a His₆-tag at the C-terminus of the enzyme sequence.

Inhibition studies of phosphonates on 5FW β PGM

Although the formation of β G1CP and β G1CF_SP TSA complexes have been extensively studied,^{7–9} the kinetic analysis of phosphonates as non-covalent inhibitors for β PGM has not been reported. Inhibition studies were performed without NH_4F , as fluorine inhibition has already been reported in the low




Fig. 4 Double-reciprocal plots for the inhibition of 50 nM β PGM with varying concentrations of β G1CP (A) and β G1CF_SP (B), along with 2 mM MgCl_2 , 0.5 mM NADP^+ , 5 U mL^{-1} G6PDH, 150 μM fructose-1,6-bisphosphate, and β G1P in 50 mM HEPES pH 7.2. ▲ 0 μM , × 2 μM , ◆ 5 μM , ■ 10 μM , ● 20 μM .



millimolar range.⁸ IC₅₀ measurements of both ligands were performed with wild-type and 5FW β PGM, however, there was no significant discrepancy in values between the two enzymes (Table 1). For 5FW β PGM, β G1CP and β G1CF_SP both show IC₅₀ values in the micromolar range (13 ± 5 μ M and 11 ± 2 μ M respectively) (Fig. S2†). Time-dependent inhibition was not observed with either inhibitor. The mode of inhibition of these inhibitors was determined from double-reciprocal plots (Fig. 4) that showed both analogues as competitive inhibitors with K_i values of 4.67 ± 0.04 μ M for β G1CP and 4.03 ± 0.03 μ M for β G1CF_SP. These values suggest that phosphonate compounds bind 5–6 times less strongly than the enzyme intermediate, β G16BP ($K_m = 0.72 \pm 0.04 \mu$ M),²⁸ whereas they show a slightly stronger binding affinity than the native substrate, β G1P.²⁸ Nonetheless, these data are measured without fluorine in the solution and so it is not representative of the inhibition, or formation constant, of the MgF₃[−] or AlF₄[−] complexes with these compounds.

X-ray structural analysis of 5FW β PGM and evidence of 5-fluoroindole ring flip

In order to better determine the origin of the observed resonances, and confirm that the labelled amino acids did not perturb protein function, the structures of 5FW β PGM apo-protein and the TSA complex with MgF₃[−] and G6P were determined. Initially, crystals of the 5FW β PGM–MgF₃[−]–G6P complex were obtained from already established conditions.²⁹ Clear density was visible for both 5FW24 and 216 (Fig. 5) showing that the labelled amino acid was incorporated and was in a similar conformation to that observed for the native protein. As the fluorine resonances indicated possible multiple conformations, the structures of the apo-protein and a new crystal form of the 5FW β PGM–MgF₃[−]–G6P complex, where crystal contacts are different in the region of W216, were also determined. In the latter, the two molecules in the asymmetric unit show two alternative orientations for 5FW216 (Fig. S19†). The orientations appear to be equally populated and it is likely that in




Fig. 6 Comparison of the conformation of labelled and unlabelled W24 in the β PGM–MgF₃[−]–G6P complex. 5FW24 β PGM is shown in magenta and β PGM in gold. The main amino acid side chains involved in ligand binding are shown. There is no discernible difference between the labelled and unlabelled proteins.

solution both orientations are possible. This accounts for the two resonances observed for 5FW216 (Fig. 2B). In the apo-protein structure, 2 conformations were also observed for 5FW24 (Fig. S20†) but with the conformation not previously observed at very low occupancy (<10%), this could account for the slight line broadening observed for the apo-protein resonance (Fig. 3A). In all closed conformation structures 5FW24 is in the same conformation as the native protein (Fig. 6), confirming that the labelled protein can act as a reporter of the state of the enzyme without interfering with activity.




Fig. 5 Density for 5FW216 after molecular replacement before the inclusion of the modified amino acid in the model (2MFo-Fc blue mesh contoured at 1 σ , Fo-Fc green mesh contoured at 3 σ). Clear positive density is observed for the fluorine atom, confirming the presence of the label.

Conclusion

In this study, incorporation of 5-fluorotryptophan into the β PGM enzyme structure has been successfully completed with high efficiency and does not perturb catalytic efficiency or protein structure as determined by X-ray crystallography and ¹⁹F NMR spectroscopy. ¹⁹F NMR studies of 5FW β PGM W216F with metal fluoride TSA complexes enabled convenient evaluation of TSA complex formation for phosphoryl transfer enzymes by facilitating observation of protein, metal fluoride species, and ligand in a single NMR spectrum at anticipated molar ratios. The discovery of 5FW24, as a resonance in the β PGM enzyme structure that reports TSA complexation, has enabled us to demonstrate that the metal fluoride complexes are representative of phosphoryl transfer in aqueous solution. This will permit screening and analysis of inhibitors that may bind to the phosphoryl transfer site and perturb the formation of metal fluoride complexes.



Experimental

Preparation of β PGM-His mutant

The His₆-Tag mutant was prepared from the pET22b(+)*pgmB* template⁸ and commercial oligonucleotide primers, incorporating a silent mutation for SacI (underlined) by removing the TAA stop codon: 5'-GAA AGA AGT TTG GCT TCA AAA GCA AAA **AGA GCT** CGA GCA CCA CCA C-3' and 5'-GTG GTG GTG CTC GAG CTC TTT TTG CTT TTG AAG CCA AAC TTC TTT C-3'. Mutant preparation was performed according to the quick-change lightning site-directed mutagenesis kit. Confirmation of the mutation was accomplished by digesting plasmids with SacI and PstI (Fig. S3†). The purified plasmid was transformed into *E. coli* BL21(DE3) and the protein was expressed according to literature procedure.³⁰ Protein purification was performed using a HiTrap 5 mL Chelating HP NTA-Ni²⁺ affinity column, eluting at a flow rate of 2.5 mL min⁻¹ with a step-wise gradient of 250 mM and 25 mM imidazole buffer. Fractions were pooled and buffer exchanged into 50 mM HEPES buffer pH 7.2, providing 30.6 g L⁻¹ of pure protein. Enzyme concentrations were determined using spectrophotometric analysis ($\epsilon_{280} = 19\,940\text{ M}^{-1}\text{ cm}^{-1}$).

Expression and purification of 5FW β PGM

pET22b(+)*pgmB*-His was expressed in *E. coli* BL21(DE3) and grown in minimal media according to the published Crowley methods.²⁴ 25 mL LB_{Amp} was inoculated with 25 μ L *E. coli* BL21(DE3) pET-22b(+)*pgmB*-His glycerol stock and incubated at 37 °C with shaking (250 rpm) overnight. 3.3 mL of the overnight culture was used to inoculate 6 \times 330 mL of LB_{Amp} in 1 L flasks. Bacterial cultures were grown at 37 °C with shaking (250 rpm) for 2–3 h until an OD₆₀₀ of ~0.6–0.8 was reached. The bacterial cultures were centrifuged at 3750 rpm for 5 min and the supernatant was discarded. The cell pellet was resuspended in 12 mL of minimal growth media (12 g L⁻¹ NaH₂PO₄, 6 g L⁻¹ K₂HPO₄, 1 g L⁻¹ NH₄Cl, 2 g L⁻¹ D-glucose, 4 mL L⁻¹ 1 M MgSO₄, and 1.8 mL L⁻¹ 1 mM FeSO₄) and distributed evenly between 6 \times 330 mL minimal media in 1 L flasks. Bacterial cultures were incubated at 37 °C with shaking (250 rpm) for 30 min. In ¹⁹F-labelling method B, 3 \times 330 mL bacterial cultures were supplemented with 1 mL of sterile L-phenylalanine, L-tyrosine, 5-fluoro-D/L-tryptophan, and glyphosate solutions for final concentrations of 60 mg L⁻¹, 60 mg L⁻¹, 120 mg L⁻¹, and 1 g L⁻¹ respectively. In ¹⁹F-labelling method A, 3 \times 330 mL bacterial cultures were supplemented with 1 mL solution of 5-fluoroindole in DMSO for a final concentration of 60 mg L⁻¹. IPTG was added to 1 mM in all 6 \times 330 mL bacterial cultures and cultures were incubated at 18 °C overnight, 250 rpm. For ¹⁵N-labeled protein, ¹⁵NH₄Cl was substituted in the minimal media for NH₄Cl. The protein was purified by the same method used for β PGM-His, providing 27.8 mg L⁻¹ of ¹⁵N- β PGM, 13.0 mg L⁻¹ of 5FW β PGM (method A) and 23.5 mg L⁻¹ of 5FW β PGM (method B) (Fig. S6†).

Preparation of β PGM-W24F mutant

W24F mutant was prepared from the pET22b(+)*pgmB*-His template and commercial oligonucleotide primers converting

Trp24 to Phe24 (bold) and incorporating a silent mutation for BglI (underlined): 5'-ATT AAT GCC AAT TTC TTC AGC CAA AGC CTT **AAA** GGC TCT AAA ATG ATA CTC TGC GGT ATC-3' and 5'-GAT ACC GCA GAG TAT CAT TTT AGA **GCC** TTT AAG GC T TTG GCT GAA GAA ATT GGC ATT AAT-3'. Mutant preparation was performed according to the quick-change lightning site-directed mutagenesis procedure and confirmation of the mutation was accomplished by digesting plasmids with BglI and BstEII (Fig. S4†). The β PGM-W24F plasmid was transformed into *E. coli* BL21(DE3) and the protein was overexpressed and purified according to the same procedure used for 5FW β PGM, providing 18.5 mg L⁻¹ of W24F 5FW β PGM (Fig. S6†).

Preparation of β PGM-W216F mutant

W216F mutant was prepared from the pET22b(+)*pgmB*-His template and commercial oligonucleotide primers converting Trp216 to Phe216 (bold) and incorporating a silent mutation for PstI (underlined): 5'-TCG AGC TCT TTT TGC TTC TGC **AG** A AAA ACT TCT TTC AAA AAT TCT AAT GTA TAG TAT GAA-3' and 5'-TTC ATA CTA TAC ATT AGA ATT TTT GAA AGA AGT **TTT** TCT GCA G AA GCA AAA AGA GCT CGA-3'. Mutant preparation was performed according to the quickchange lightning site-directed mutagenesis procedure and confirmation of the mutation was accomplished by digesting plasmids with PstI (Fig. S5†). The β PGM-W216F plasmid was transformed into *E. coli* BL21(DE3) and the protein was overexpressed and purified according to the same procedure used for 5FW β PGM, using only method B for ¹⁹F-labelling, providing 45.8 mg L⁻¹ of W216F 5FW β PGM (Fig. S7†).

NMR methods

All NMR spectra were recorded on a Bruker Avance 500 MHz spectrometer equipped with a 5 mm Smart Probe, operating at 470 MHz for fluorine. 1D ¹⁹F NMR were recorded at 5 °C with a zgbsfhhgqn (for G6P complexes) or zgfhigqn (for G1CP and G1CF_sP complexes) pulse program and acquired over 3000–31 150 transients with a recycle delay of 2.5 s. MgF₃-TSA samples contained 1 mM (5FW β PGM and 5FW β PGM W24F) or 1.6 mM (5FW β PGM W216F) protein, 1 mM DTT, 5 mM MgCl₂, 10 mM NH₄F, 5 mM substrate and 10% D₂O in 50 mM HEPES pH 7.2. AlF₄-TSA complexes were prepared similarly with the addition of 1 equivalent AlCl₃. All ¹⁹F NMR were referenced with NH₄F (~119.5 ppm). ¹H-¹⁵N HSQC were recorded at 27 °C with a hsqcetgpsi pulse program and acquired over 128 scans. 1 mM DSS was used to reference ¹H NMR shifts. Samples contained 500 μ M 5FW or unlabeled ¹⁵N β PGM, 5 mM MgCl₂ and 10% D₂O in 50 mM HEPES pH 7.2.

β PGM K_m and k_{cat} determination

All kinetic data was obtained using spectrophotometric analysis. The turnover of β G1P (commercially available) to G6P was monitored by the accumulation of NADPH ($\epsilon_{340} = 6.22\text{ mM}^{-1}\text{ cm}^{-1}$) via a coupled reaction to glucose-6-phosphate dehydrogenase (G6PDH). Kinetic assays were performed in 100 μ L total volume at 25 °C in 50 mM HEPES pH 7.2 and

contained 2 mM MgCl₂, 0.5 mM NADP⁺, 5 U mL⁻¹ G6PDH, 150 µM α -fructose-1,6-bisphosphate, 50 nM 5FW β PGM, and 0–200 µM β G1P unless otherwise stated. Reactions were initiated with the addition of substrate. Steady state rates were obtained from the linear portions of time vs. A_{340} plots. Calculated errors are a result of standard error.

β PGM inhibition assays

Assays were performed in 100 µL total volume at 25 °C in 50 mM HEPES pH 7.2. IC₅₀ assays included 2 mM MgCl₂, 0.5 mM NADP⁺, 5 U mL⁻¹ G6PDH, 150 µM α -fructose-1,6-bisphosphate, 10 µM β G1P, 50 nM 5FW β PGM and 0–5 mM inhibitor. Assays for K_i determination included 2 mM MgCl₂, 0.5 mM NADP⁺, 5 U mL⁻¹ G6PDH, 150 µM fructose-1,6-bisphosphate, 50 nM β PGM, 0–200 µM β G1P and were evaluated for different inhibitor concentrations (0–20 µM). All reactions were initiated with the addition of substrate. Calculated errors are a result of standard error.

Crystallization, data collection and refinement

Purified 5FW β PGM was concentrated to 10 mg mL⁻¹ and used for sitting drop vapour diffusion crystallization experiments. Orthorhombic crystals of the 5FW β PGM-MgF₃⁻-G6P complex were obtained from already established conditions²⁹ and cryo-cooled directly.³¹ New crystal conditions for the apo-protein and 5FW β PGM-MgF₃⁻-G6P complex were established at the EMBL High Throughput Crystallization (HTX) Laboratory (Grenoble, France). The protein was set up in sitting-drop vapour-diffusion plates, with drops consisting of 100 nL sample plus 100 nL of reservoir solution. A number of crystals in different crystallization conditions were obtained. Crystals of the apo-protein grew at 20 °C in 1–7 days from a solution of 0.2 M calcium chloride, 20% (w/v) PEG 6000 and 0.1 M tris (pH 8). Crystals of a new monoclinic crystal form of the 5FW β PGM-MgF₃⁻-G6P complex grew in 20% (w/v) PEG 5000MME and 0.1 M sodium acetate. Crystals were harvested and cryo-cooled automatically using the CrystalDirect robot. X-ray diffraction data were collected by the autonomous ESRF beamline MASSIF-1³² using automatic protocols for the location and optimal centring of crystals.³³ The beam diameter was selected automatically to match the crystal volume of highest homogeneous quality. Strategy calculations accounted for flux and crystal volume in the parameter prediction for complete data sets. Data reduction was performed with XDS³⁴ followed by AIMLESS.³⁵ The crystals of the apo-protein belonged to the orthorhombic space group $P2_{1}2_{1}2$, with two molecules in the asymmetric unit coordinating a Ca²⁺. The new crystal form of the 5FW β PGM-MgF₃⁻-G6P complex was in the monoclinic space group $P2_1$ with two molecules in the asymmetric unit (Table S1†). The structures were solved using PHASER_MR³⁶ implemented in CCP4 using the coordinates of the open conformation of β -PGM (PDB code 2WHE,²⁹ apo-protein) and the native β PGM-MgF₃⁻-G6P structure (PDB code 2WF5;²⁹ 5FW β PGM-MgF₃⁻-G6P complex) as initial search models. Refinement was carried out using REFMAC5³⁷ and PHENIX³⁸ and by manual rebuilding with COOT.³⁹

Data deposition

The atomic coordinates and structure factors have been deposited in the protein data bank with codes 5FW β PGM apo-protein: 5OLW, 5FW β PGM-MgF₃⁻-G6P complex: 5OLX and 5FW β PGM-MgF₃⁻-G6P complex monoclinic crystal form: 5OLY.

Conflicts of interest

There are no conflicts of interest to declare.

Acknowledgements

We thank NSERC, CIHR, and NSHRF for financial support of this research. We thank Nicole E. McCormick for her help with mutant preparation and protein expression.

Notes and references

- 1 M. W. Bowler, M. J. Cliff, J. P. Waltho and G. M. Blackburn, *New J. Chem.*, 2010, **34**, 784.
- 2 Y. Jin, N. G. Richards, J. P. Waltho and G. M. Blackburn, *Angew. Chem., Int. Ed.*, 2017, **56**, 4110.
- 3 M. E. Glassier, J. A. Gerlt and P. C. Babbitt, *Curr. Opin. Chem. Biol.*, 2006, **10**, 492.
- 4 S. Lahiri, G. Zhang, D. Dunaway-Mariano and K. Allen, *Biochemistry*, 2002, **41**, 8351.
- 5 S. D. Lahiri, G. F. Zhang, D. Dunaway-Mariano and K. N. Allen, *Science*, 2003, **299**, 2067.
- 6 J. Dai, L. Finci, C. Zhang, S. Lahiri, G. Zhang, E. Peisach, K. N. Allen and D. Dunaway-Mariano, *Biochemistry*, 2009, **48**, 1984.
- 7 Y. Jin, D. Bhattacharjee, E. Pellegrini, S. M. Forget, N. J. Baxter, M. J. Cliff, M. W. Bowler, D. L. Jakeman, G. M. Blackburn and J. P. Waltho, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, 12384.
- 8 N. J. Baxter, L. F. Olgun, M. Golicnik, G. Feng, A. M. Hounslow, W. Bermel, G. M. Blackburn, F. Hollfelder, J. P. Waltho and N. H. Williams, *Proc. Natl. Acad. Sci. U. S. A.*, 2006, **103**, 14732.
- 9 N. J. Baxter, G. M. Blackburn, J. P. Marston, A. M. Hounslow, M. J. Cliff, W. Bermel, N. H. Williams, F. Hollfelder, D. E. Wemmer and J. P. Waltho, *J. Am. Chem. Soc.*, 2008, **130**, 3952.
- 10 J. L. Griffin, M. W. Bowler, N. J. Baxter, K. N. Leigh, H. R. W. Dannatt, A. M. Hounslow, G. M. Blackburn, C. E. Webster, M. J. Cliff and J. P. Waltho, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, **109**, 6910.
- 11 E. Matei and A. M. Gronenborn, *Angew. Chem., Int. Ed.*, 2016, **55**, 150.
- 12 C. T. Gee, E. J. Koleski and W. C. Pomerantz, *Angew. Chem., Int. Ed.*, 2015, **54**, 3735.
- 13 F. Yang, X. Yu, C. Liu, C. X. Qu, Z. Gong, H. D. Liu, F. H. Li, H. M. Wang, D. F. He and F. Yi, *Nat. Commun.*, 2015, **6**, 1.



14 E. W. Leung, H. Yagi, J. R. Harjani, M. D. Mulcair, M. J. Scanlon, J. B. Baell and R. S. Norton, *Chem. Biol. Drug Des.*, 2014, **84**, 616.

15 R. Curtis-Maroma, D. Dokoa, M. L. Rowea, K. L. Richardsa, R. A. Williamson and M. J. Howard, *Org. Biomol. Chem.*, 2014, **12**, 3808.

16 N. K. Mishra, A. K. Urick, S. W. J. Ember, E. Schonbrunn and W. C. Pomerantz, *ACS Chem. Biol.*, 2014, **9**, 2755.

17 J. Suarez, A. Haapalainen, S. M. Cahill, M. C. Ho, F. N. Yan, S. C. Almo and V. L. Schramm, *Chem. Biol.*, 2013, **20**, 212.

18 J. J. Liu, R. Horst and V. Katritch, *Science*, 2012, **335**, 1106.

19 J. L. Kitevski-LeBlanc and R. S. Prosser, *Prog. Nucl. Magn. Reson. Spectrosc.*, 2012, **62**, 1.

20 N. V. Visser, A. H. Westphal, S. M. Nabuurs, A. van Hoek, C. P. M. van Mierlo, A. J. W. G. Visser, J. Broos and H. van Amerongen, *FEBS Lett.*, 2009, **583**, 2785.

21 C. Frieden, S. D. Hoeltzli and J. G. Ban, *Methods Enzymol.*, 2004, **380**, 400.

22 M. Sarker, K. E. Orrell, L. Xu, M. Tremblay, J. J. Bak, X. Liu and J. K. Rainey, *Biochemistry*, 2016, **55**, 3048.

23 K. E. Arntson and W. C. K. Pomerantz, *J. Med. Chem.*, 2016, **59**, 5158.

24 P. B. Crowley, C. Kyne and W. B. Monteith, *Chem. Commun.*, 2012, **48**, 10681.

25 M. D. Sorensen, S. M. Kristensen, S. Bjorn, K. Noris, O. Olsen and J. J. Led, *J. Biol. NMR*, 1996, **8**, 391.

26 H. Hansson, P. T. Mattson, P. Allard, P. Haapaniemi, M. Vihinen, C. I. E. Smith and T. Hard, *Biochemistry*, 1998, **37**, 2912.

27 G. F. Zhang, J. Dai, L. B. Wang, D. Dunaway-Mariano, L. W. Tremblay and K. N. Allen, *Biochemistry*, 2005, **44**, 9404.

28 M. Golicnik, L. F. Olguin, G. Feng, N. J. Baxter, J. P. Waltho, N. H. Williams and F. Hollfelder, *J. Am. Chem. Soc.*, 2009, **131**, 1575.

29 N. J. Baxter, M. W. Bowler, T. Alizadeh, M. J. Cliff, A. M. Hounslow, B. Wu, D. B. Berkowitz, N. H. Williams, G. M. Blackburn and J. P. Waltho, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**, 4555.

30 S. D. Lahiri, G. Zhang, P. Radstrom, D. Dunaway-Mariano and K. N. Allen, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2002, **58**, 324.

31 E. Pellegrini, D. Piano and M. W. Bowler, *Acta Crystallogr.*, 2011, **67**, 902.

32 M. W. Bowler, D. Nurizzo, R. Barrett, A. Beteva, M. Bodin, H. Caserotto, S. Delagriere, F. Dobias, D. Flot, T. Giraud, N. Guichard, M. Guijarro, M. Lentini, G. A. Leonard, S. McSweeney, M. Oskarsson, W. Schmidt, A. Snigirev, D. von Stetten, J. Surr, O. Svensson, P. Theveneau and C. Mueller-Dieckmann, *J. Synchrotron Radiat.*, 2015, **22**, 1540.

33 O. Svensson, S. Malbet-Monaco, A. Popov, D. Nurizzo and M. W. Bowler, *Acta Crystallogr., Sect. D: Struct. Biol.*, 2015, **71**, 1757.

34 W. Kabsch, *Acta Crystallogr., Sect. D: Struct. Biol.*, 2010, **66**, 125.

35 P. R. Evans and G. N. Murshudov, *Acta Crystallogr., Sect. D: Struct. Biol.*, 2013, **69**, 1204.

36 A. J. McCoy, R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni and R. J. Read, *J. Appl. Crystallogr.*, 2007, **40**, 658.

37 G. Murshudov, A. Vagin and E. Dodson, *Acta Crystallogr., Sect. D: Struct. Biol.*, 1997, **53**, 240.

38 P. V. Afonine, R. W. Grosse-Kunstleve, N. Echols, J. J. Headd, N. W. Moriarty, M. Mustyakimov, T. C. Terwilliger, A. Urzhumtsev, P. H. Zwart and P. D. Adams, *Acta Crystallogr., Sect. D: Struct. Biol.*, 2012, **68**, 352.

39 P. Emsley and K. Cowtan, *Acta Crystallogr., Sect. D: Struct. Biol.*, 2004, **60**, 2126.

